AR083267A1 - Combinaciones farmaceuticas - Google Patents
Combinaciones farmaceuticasInfo
- Publication number
- AR083267A1 AR083267A1 ARP110103630A ARP110103630A AR083267A1 AR 083267 A1 AR083267 A1 AR 083267A1 AR P110103630 A ARP110103630 A AR P110103630A AR P110103630 A ARP110103630 A AR P110103630A AR 083267 A1 AR083267 A1 AR 083267A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- kinase
- mtor
- treatment
- mtor inhibitor
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 2
- 230000003197 catalytic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 abstract 1
- 101150097381 Mtor gene Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Combinación farmacéutica que comprende: (a) un inhibidor catalítico de mTor, tal como una cinasa de fosfatidil-inositol-3 catalítica (PI3K), y un compuesto inhibidor de mTor, el cual es un derivado de imidazo-quinolina, y (b) cuando menos un compuesto aloestérico inhibidor de mTor, y opcionalmente, cuando menos un vehículo farmacéuticamente aceptable, para su uso simultáneo, separado, o en secuencia, en particular para el tratamiento de las enfermedades proliferativas dependientes de cinasa del objetivo de mamífero de rapamicina (mTOR); y a los usos de esta combinación en el tratamiento de las enfermedades proliferativas dependientes de la cinasa mTor; a una composición farmacéutica, la cual comprende dicha combinación; al uso de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a un paquete o producto comercial que comprende esta combinación como una preparación combinada, para su uso simultáneo, separado, o en secuencia; y a un método para el tratamiento de un animal de sangre caliente, en especial de un ser humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38944510P | 2010-10-04 | 2010-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083267A1 true AR083267A1 (es) | 2013-02-13 |
Family
ID=44802399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103630A AR083267A1 (es) | 2010-10-04 | 2011-09-30 | Combinaciones farmaceuticas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130178479A1 (es) |
| EP (1) | EP2624831A1 (es) |
| JP (1) | JP2013538876A (es) |
| KR (1) | KR20130108330A (es) |
| CN (1) | CN103153305A (es) |
| AR (1) | AR083267A1 (es) |
| AU (1) | AU2011312372A1 (es) |
| BR (1) | BR112013008074A2 (es) |
| CA (1) | CA2812786A1 (es) |
| CL (1) | CL2013000895A1 (es) |
| CO (1) | CO6710908A2 (es) |
| EC (1) | ECSP13012541A (es) |
| MA (1) | MA34554B1 (es) |
| MX (1) | MX2013003833A (es) |
| NZ (1) | NZ608375A (es) |
| PE (1) | PE20140203A1 (es) |
| PH (1) | PH12013500581A1 (es) |
| RU (1) | RU2013120357A (es) |
| SG (1) | SG188521A1 (es) |
| TW (1) | TW201217374A (es) |
| WO (1) | WO2012047775A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012213080B2 (en) | 2011-01-31 | 2014-03-27 | Novartis Ag | Novel heterocyclic derivatives |
| EP2675450B1 (en) * | 2011-02-16 | 2016-02-10 | Novartis AG | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| WO2013192367A1 (en) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2014028566A1 (en) * | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| MX2017014776A (es) | 2015-05-20 | 2018-02-15 | Novartis Ag | Combinacion farmaceutica de everolimus con dactolisib. |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| EP3544608A1 (en) | 2016-11-23 | 2019-10-02 | Novartis AG | Methods of enhancing immune response with everolimus, dactolisib or both |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101360495B (zh) * | 2005-11-14 | 2012-03-14 | 阿里亚德医药股份有限公司 | 对癌症病人给药mTOR抑制剂 |
| CN101616672A (zh) * | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
-
2011
- 2011-09-30 AR ARP110103630A patent/AR083267A1/es unknown
- 2011-10-03 JP JP2013532854A patent/JP2013538876A/ja active Pending
- 2011-10-03 MA MA35783A patent/MA34554B1/fr unknown
- 2011-10-03 WO PCT/US2011/054536 patent/WO2012047775A1/en not_active Ceased
- 2011-10-03 CN CN201180048544XA patent/CN103153305A/zh active Pending
- 2011-10-03 MX MX2013003833A patent/MX2013003833A/es unknown
- 2011-10-03 PH PH1/2013/500581A patent/PH12013500581A1/en unknown
- 2011-10-03 RU RU2013120357/15A patent/RU2013120357A/ru not_active Application Discontinuation
- 2011-10-03 US US13/876,021 patent/US20130178479A1/en not_active Abandoned
- 2011-10-03 EP EP11770611.9A patent/EP2624831A1/en not_active Withdrawn
- 2011-10-03 KR KR1020137008528A patent/KR20130108330A/ko not_active Withdrawn
- 2011-10-03 BR BR112013008074A patent/BR112013008074A2/pt not_active Application Discontinuation
- 2011-10-03 PE PE2013000776A patent/PE20140203A1/es not_active Application Discontinuation
- 2011-10-03 AU AU2011312372A patent/AU2011312372A1/en not_active Abandoned
- 2011-10-03 TW TW100135797A patent/TW201217374A/zh unknown
- 2011-10-03 SG SG2013018254A patent/SG188521A1/en unknown
- 2011-10-03 CA CA2812786A patent/CA2812786A1/en not_active Abandoned
- 2011-10-03 NZ NZ608375A patent/NZ608375A/en not_active IP Right Cessation
-
2013
- 2013-04-01 EC ECSP13012541 patent/ECSP13012541A/es unknown
- 2013-04-03 CL CL2013000895A patent/CL2013000895A1/es unknown
- 2013-04-08 CO CO13090543A patent/CO6710908A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012047775A1 (en) | 2012-04-12 |
| CA2812786A1 (en) | 2012-04-12 |
| CO6710908A2 (es) | 2013-07-15 |
| JP2013538876A (ja) | 2013-10-17 |
| KR20130108330A (ko) | 2013-10-02 |
| MX2013003833A (es) | 2013-06-28 |
| BR112013008074A2 (pt) | 2016-06-14 |
| RU2013120357A (ru) | 2014-11-20 |
| ECSP13012541A (es) | 2013-06-28 |
| SG188521A1 (en) | 2013-04-30 |
| MA34554B1 (fr) | 2013-09-02 |
| AU2011312372A1 (en) | 2013-04-04 |
| EP2624831A1 (en) | 2013-08-14 |
| PH12013500581A1 (en) | 2013-05-20 |
| CN103153305A (zh) | 2013-06-12 |
| TW201217374A (en) | 2012-05-01 |
| NZ608375A (en) | 2014-08-29 |
| PE20140203A1 (es) | 2014-02-28 |
| CL2013000895A1 (es) | 2013-09-27 |
| US20130178479A1 (en) | 2013-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012541A (es) | Combinaciones farmacéuticas | |
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR122743A2 (es) | Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| DOP2010000012A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| DOP2010000013A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| UY33286A (es) | Derivados de triazina disustituidos farmaceuticamente activos | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| BR112014018910A8 (pt) | Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores | |
| CL2012003227A1 (es) | Compuestos macrociclicos que comprenden en el ciclo una porcion pirazolo[1,5-a]pirimidina, inhibidores de quinasa trk; composicion farmaceutica; proceso de preparación; y metodo para tratar un trastorno seleccionado de dolor, cancer, inflamacion, enfermedad neurodegenerativa o infeccion por trypanosoma cruzi. | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| ECSP13012994A (es) | COMBINACIÓN DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR | |
| CL2007000781A1 (es) | Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| UY33745A (es) | Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas | |
| CL2008001766A1 (es) | Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis. | |
| AR081024A1 (es) | Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |